RHAG and prostate cancer: Rh2 was also able toinhibit cancer cells angiogenesis via the inhibition of vascular endothelial growth factor A (VEGF-A) protein in GBM cells [83], induce cell detachment and modulate mitogen-activated protein (MAP) kinases in the prostate cancer cell lines, LNCaP and PC3 [56], in addition to hepatic cellular carcinoma HepG2 cells [10].